Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278898 | 0.78 | ALOX15 (0.76) | ALOX15ALDH1A1KDM4EHTTHPGD | |
| SCHEMBL7145906 | 0.75 | ALOX15 (0.51) | ALOX15ALDH1A1POLBHPGD | |
| SCHEMBL9867321 | 0.73 | ALOX15 (0.49) | ALOX15ALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL18325474 | 0.73 | ALOX15 (0.67) | ALOX15ALDH1A1KDM4EGAAGLA | |
| SCHEMBL6929250 | 0.71 | POLB (0.59) | ALDH1A1KDM4ETDP1POLBGAA | |
| SCHEMBL6930588 | 0.71 | ALDH1A1 (0.37) | ALDH1A1KDM4ETDP1POLBGAA | |
| SCHEMBL9030749 | 0.70 | CHRM2 (0.52) | ALDH1A1 | |
| SCHEMBL28946844 | 0.68 | ALOX15 (0.46) | ALOX15KDM4EHTTSMN1; SMN2IRAK4 | |
| SCHEMBL6930770 | 0.65 | LMNA (0.70) | ALDH1A1KDM4EPOLBGAARECQL | |
| SCHEMBL15329166 | 0.64 | ALOX15 (1.00) | ALOX15ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777659-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1997-06-11 | — | — | EP | claimed |
| WO-1996005181-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| EP-1017395-A4 | METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1030672-A1 | METHOD FOR TREATING ATTENTION DEFICIT DISORDER | Merck & Co., Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-1017395-A1 | METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | Merck & Co., Inc. (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001779-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-05-24 | — | — | EP | disclosed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | disclosed |
| EP-0977573-A1 | USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999059583-A1 | METHOD FOR TREATING OR PREVENTING CHRONIC NONBACTERIAL PROSTATITIS AND PROSTATODYNIA | MERCK & CO., INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0929303-A2 | CNS-PENETRANT NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSANT AND/OR AN ANTI-ANXIETY AGENT | MERCK SHARP & DOHME LTD. (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1999027938-A1 | METHOD FOR TREATING OR PREVENTING PSYCHOSOMATIC AND PSYCHOIMMUNOLOGIC DISORDERS | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| WO-1999025364-A1 | METHOD FOR TREATING ATTENTION DEFICIT DISORDER | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999009987-A1 | METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999007374-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007373-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007375-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998047514-A1 | USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998015277-A2 | CNS-PENETRANT NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSANT AND/OR AN ANTI-ANXIETY AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-04-16 | — | — | WO | disclosed |